Delivery Order SPE2DR25D1202-SPE2DR26F72CX
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units, valued at $1,384.82 under a firm fixed price contract structure. This delivery order represents a competitive award with no set-aside designation and is scheduled for completion by September 17, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units, valued at $1,078.57 with a firm fixed price structure. This is a competitively awarded, non-set-aside contract with an ultimate completion date of October 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injectors valued at $3,328.44. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The order has an ultimate completion date of November 13, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,813.90. This firm fixed-price delivery order is scheduled for completion by August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive capability...
- The Defense Logistics Agency awarded a $2,320.60 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector units. The award was made on November 17, 2025, with an ultimate completion date of November 18, 2025, and represents a non-set-aside competitive award. Performance will be executed from AmerisourceBergen's Conshohocken, Pennsylvania location, the company's corporate headquarters. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units valued at $1,954.96. This is a firm fixed price delivery order with an ultimate completion date of August 21, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this...
- The Defense Logistics Agency awarded a delivery order valued at $1,197.19 to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units. This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 21, 2025, with performance fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation, reflecting AmerisourceBergen's capability to compete...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injectors valued at $1,400.67. This firm fixed-price delivery order, with an ultimate completion date of November 18, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was made without a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,731.01. This firm fixed-price delivery order, which is due for completion by August 7, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award carries no set-aside designation, indicating it was competitively awarded. The pharmaceutical...
- The Defense Logistics Agency awarded a $1,711.16 delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector units on September 5, 2025, with an ultimate completion date of September 8, 2025. This firm fixed-price contract represents a non-set-aside competitive award for pharmaceutical supply to support federal medical procurement needs. The work will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DR25D1202Indefinite Delivery Contract
- SPE2DR25D1202-SPE2DR26F72CXDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units valued at $2,103.60. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by November 13, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies an extensive portfolio of medications and medical supplies to support military and veteran healthcare systems. The company's demonstrated capability to fulfill federal procurement requirements through open competition, combined with its established prime vendor status, positions it as a key provider for the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 11/12/25 |